somapacitan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
growth hormone derivatives 5413 1338578-34-9

Description:

MoleculeDescription

Molfile

Synonyms:

  • somapacitan
  • somapacitan-beco
  • sogroya
  • NNC0195-0092
  • NN8640
  • somapacitan (genetical recombination)
Somapacitan-beco is a human growth hormone (hGH) analog. It binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by insulin-like growth factor I (IGF-I) produced in the liver, while others are primarily a consequence of the direct effects of somapacitan-beco.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Aug. 28, 2020 FDA NOVO NORDISK INC
March 31, 2021 EMA Novo Nordisk A/S
June 26, 2023 PMDA Novo Nordisk Pharma Ltd.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H01AC07 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
Somatropin and somatropin agonists

Related Drugs by ATC class:

H01AC Somatropin and somatropin agonists 8 drugs
lonapegsomatropinmecaserminmecasermin rinfabatesermorelinsomatremsomatrogonsomatropintesamorelin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Adult growth hormone deficiency indication 421684006
Diabetic retinopathy contraindication 4855003 DOID:8947
Malignant neoplastic disease contraindication 363346000 DOID:162




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Growth hormone receptor Membrane receptor Kd 8.04 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
D11194 KEGG_DRUG
8FOJ430U94 UNII
C4726770 UMLSCUI
CHEBI:755778 CHEBI
JG5 PDB_CHEM_ID
CHEMBL3707290 ChEMBL_ID
129894493 PUBCHEM_CID
DB15093 DRUGBANK_ID
10019 INN_ID
C000718308 MESH_SUPPLEMENTAL_RECORD_UI
C000594654 MESH_SUPPLEMENTAL_RECORD_UI
898157004 SNOMEDCT_US
4042238 VANDF
4042239 VANDF
338169 MMSL
38779 MMSL
d09620 MMSL
018501 NDDF
2557373 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SOGROYA HUMAN PRESCRIPTION DRUG LABEL 1 0169-2030 INJECTION, SOLUTION 6.70 mg SUBCUTANEOUS BLA 32 sections
SOGROYA HUMAN PRESCRIPTION DRUG LABEL 1 0169-2035 INJECTION, SOLUTION 3.30 mg SUBCUTANEOUS BLA 32 sections
SOGROYA HUMAN PRESCRIPTION DRUG LABEL 1 0169-2037 INJECTION, SOLUTION 10 mg SUBCUTANEOUS BLA 32 sections